PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

REGULATED INFORMATION

GHENT, Belgium, 6 July 2017 - Ablynx (([Euronext Brussels: ABLX, OTC:ABYLY) today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from Bank of America Corporation on 5 July 2017.

Bank of America Corporation (taking into account the holdings of its subsidiary undertakings) notified Ablynx that they have dropped below the 5% threshold as of 28 June 2017 and now hold a total of 3,038,688 shares with voting rights, representing 4.97% of the current 61,133,199 outstanding Ablynx shares (versus 5.24% notified previously).

The notified details are presented below:

Name of select subsidiaries of Bank of America Corporation	% of shares and voting rights		% of shares and voting rights held through financial instruments		Total of both
	Shares	Voting rights	Shares	Voting rights	Shares	Voting rights
Merrill Lynch Professional Clearing Corp.	4.96%	4.96%			4.96%	4.96%
Merrill Lynch Financial Markets, Inc.			0.01%	0.01%	0.01%	0.01%
TOTAL	4.96%	4.96%	0.01%	0.01%	4.97%	4.97%

Merrill Lynch Professional Clearing Corporation and Merrill Lynch Financial Markets, Inc. are controlled by Bank of America Corporation. Bank of America Corporation is not a controlled entity.

Full versions of all transparency notifications are available on Ablynx website, under the section Investors.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

For more information, please contact

Ablynx:

Dr Edwin Moses

CEO

t:   +32 (0)9 262 00 07

m: +32 (0)473 39 50 68

e:  edwin.moses@ablynx.com

Lies Vanneste

Director Investor Relations

t:   +32 (0)9 262 01 37

m: +32 (0)498 05 35 79

e:  lies.vanneste@ablynx.com

Follow us on Twitter @AblynxABLX

Ablynx media/analyst relations

FTI Consulting:

Julia Phillips, Brett Pollard, Mo Noonan

t: +44 20 3727 1000

e: ablynx@fticonsulting.com

Attachments:

http://www.globenewswire.com/NewsRoom/AttachmentNg/e498fac9-c472-4d5e-b840-daec55a308f7